Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Abstract

Correction: Journal of Hematology & Oncology (2024) 17:86

https://doi.org/10.1186/s13045-024-01606-w

The authors’ names in the authorship of the original article were mistakenly inverted and have since been amended.

Authors and Affiliations

1. CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France

   Marion Alcantara

2. Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France

   Marion Alcantara & Carole Soussain

3. Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France

   Marion Chevrier

4. Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France

   Fabrice Jardin

5. Service d’Hématologie, Institut Bergonié, Bordeaux, France

   Anna Schmitt

6. Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

   Caroline Houillier & Khê Hoang-Xuan

7. Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France

   Lucie Oberic

8. AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France

   Olivier Chinot

9. Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France

   Franck Morschhauser

10. Service d’Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France

    Frédéric Peyrade

11. Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France

    Roch Houot

12. Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France

    Hervé Ghesquieres

13. Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France

    Carole Soussain

Authors

1. Marion AlcantaraView author publications

   You can also search for this author in PubMed Google Scholar

2. Marion ChevrierView author publications

   You can also search for this author in PubMed Google Scholar

3. Fabrice JardinView author publications

   You can also search for this author in PubMed Google Scholar

4. Anna SchmittView author publications

   You can also search for this author in PubMed Google Scholar

5. Caroline HouillierView author publications

   You can also search for this author in PubMed Google Scholar

6. Lucie ObericView author publications

   You can also search for this author in PubMed Google Scholar

7. Olivier ChinotView author publications

   You can also search for this author in PubMed Google Scholar

8. Franck MorschhauserView author publications

   You can also search for this author in PubMed Google Scholar

9. Frédéric PeyradeView author publications

   You can also search for this author in PubMed Google Scholar

10. Roch HouotView author publications

    You can also search for this author in PubMed Google Scholar

11. Khê Hoang-XuanView author publications

    You can also search for this author in PubMed Google Scholar

12. Hervé GhesquieresView author publications

    You can also search for this author in PubMed Google Scholar

13. Carole SoussainView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carole Soussain.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s13045-024-01606-w.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Alcantara, M., Chevrier, M., Jardin, F. et al. Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. J Hematol Oncol 17, 98 (2024). https://doi.org/10.1186/s13045-024-01620-y

Download citation

• Published: 19 October 2024

• DOI: https://doi.org/10.1186/s13045-024-01620-y

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative